Q4 2024 Spero Therapeutics Inc Earnings Call Transcript
Key Points
- Spero Therapeutics Inc (SPRO) is advancing its lead product candidate, tebipenem HBr, in a Phase 3 trial, which could become the first broad-spectrum oral carbapenem for complicated urinary tract infections.
- The company has a partnership with GSK for the co-development of tebipenem HBr, which could lead to significant milestone payments if regulatory and commercialization efforts are successful.
- Spero Therapeutics Inc (SPRO) has sufficient cash and cash equivalents to fund operations into Q2 2026, providing financial stability for ongoing projects.
- The Phase 3 PIVOT-PO trial for tebipenem HBr is designed to address a significant unmet need in the treatment of complicated UTIs, potentially reducing hospital stays by offering an oral alternative to IV therapy.
- The company is conducting a pre-specified interim analysis for the Phase 3 trial of tebipenem HBr, with results expected in the second quarter of 2025, which could accelerate the development timeline if successful.
- Spero Therapeutics Inc (SPRO) reported a decrease in total revenue for 2024 compared to 2023, primarily due to reduced collaboration revenue from agreements with GSK and Pfizer.
- The company experienced a significant increase in R&D expenses year-over-year, driven by increased clinical trial activity, which contributed to a net loss for the year.
- The Phase 2A trial for SPR720 did not meet its primary endpoint, and there were dose-limiting safety signals, including cases of reversible Grade 3 hepatotoxicity.
- Spero Therapeutics Inc (SPRO) decided to discontinue development of SPR206, an IV-administered antibiotic, following a pipeline review and reprioritization.
- The company reported a net loss of $68.4 million for the year ended December 31, 2024, compared to a net income in the previous year, indicating financial challenges.
Good afternoon and welcome to the Spero Therapeutics fourth-quarter and full-year 2024 earnings conference call. At this time, all participants are on listen-only mode. Following the company's formal remarks, we will open up the call for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcement on the Spero Therapeutics website at www.sperotherapeutics.com.
At this time, I would like to turn the call over to Shai Biran, Senior Director Investor Relations. Mr. Biran, please go ahead.
Thank you, operator. And thank you all for participating in today's conference call. This afternoon, Spero Therapeutics released financial results and provided a business update for the fourth-quarter and full-year 2024. The press release is available on the Investors page of the Spero Therapeutics website.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
